Rech, J., Hagen, M., Englbrecht, M., Haschka, J., Reiser, M., Kleyer, A., Hueber, A., Manger, B., Figuereido, C., Cobra, J. F., Tony, H., Finzel, S., Kleinert, S., Wendler, J., Schuch, F., Ronneberger, M., Feuchtenberger, M., Fleck, M., Manger, K., Ochs, W., Schmitt-Haendle, M., Lorenz, H., Nuesslein, H., Alten, R., Henes, J., Krueger, K., & Schett, G. (n.d.). fRI0098 Elevated multi-biomarker disease activity (MBDA) predicts relapses in ra patients in sustained remission tapering tumour necrosis factor inhibitor therapy- results from the randomized controlled retro study. Annals of the rheumatic diseases, 76, 516–517. http://access.bl.uk/ark:/81055/vdc_100135140741.0x00005b